The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery

Current Clinical Pharmacology

Volumn 8, Issue 1, 2013, Pages 67-72

  Chen, Cuiping ^a   Cowles, Verne E ^a   Sweeney, Michael ^a  

^a Pharmacokinetics Depomed Inc   (United States)

Author keywords

Drug transporter; Gabapentin; Gastroretentive delivery; Immediate release; Oral absorption; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN; GABAPENTIN; METFORMIN; PLACEBO;

ARTICLE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; INTESTINE ABSORPTION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; SOMNOLENCE;

EID: 84873166517     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711308010009     Document Type: Article

References (34)

1. Neurontin® package insert, Parke-Davis, Division of Pfizer Inc, NY, NY 10017. April 2009.
2. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13: 1153-69.
3. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol 2004; 63: 959-65.
4. McLean MJ. Gabapentin. Epilepsia 1995; 36: S73-S86.
5. Neurontin® capules, Neurontin® tablets, Neurontin® oral solution. Summary of product characteristics. (Eds). Pfizer Inc, April 2009.
6. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008; 48: 1378-88.
7. Johnson P, Becker L, Halpern R, Sweeney M. Dosing patterns, therapy outcomes, and health care costs among patients with postherpetic neuralgia (PHN) treated with gabapentin or pregabalin. Pharamcoeconomics 2012.
8. Gralise® gabapentin once-daily tablet. http://www.rxlist.com/gralisedrug.htm (Accessed Jan 7, 2012).
9. Bockbrader HN. Clinical pharmacokinetics of gabapentin. Drugs of Today 1995; 31: 613-19.
10. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993; 10: 276-81.
11. Buxton IL. Pharmacokinetics and pharmacodynamics. In: Bruton, Lazo, Parker, Ed. Goodman & Gilman's the pharmacological basis of therapeutics. McGraw Hill 2006; pp. 1-40.
12. Meier Y, Eloranta JJ, Darimont J, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Disp 2007; 35: 590-94.
13. Kriel RL, Birnbaum AK, Cloyd JC, Ricker BJ, Jones Saete C, Caruso KJ. Failure of absorption of gabapentin after rectal administration. Epilepsia 1997; 38: 1242-44.
14. Uchino H, Kanai Y, Kim do K, et al. Transport of amino acidrelated compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 2002; 61: 729-37.
15. Dave MH, Schulz N, Zecevic M, Wagner CA, Verrey F. Expression of heteromeric amino acid transporters along the murine intestine. J Physiol 2004; 558: 597-610.
16. Bolger MB, Lukacova V, Woltosz WS. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J 2009; 11: 353-63.
17. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307-35.
18. Hou SY, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst 2003; 20: 459-97.
19. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention, J Control Release 2000; 63: 235-59.
20. Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993; 10: 143-95.
21. Murphy CS, Pillay V, Choonara YE, du Toit LC. Gastroretentive drug delivery systems: current developments in novel system design and evaluation. Curr Drug Deliv 2009; 6: 451-60.
22. Berner B, Cowles VE. Case studies in swelling polymeric gastric retentive tablets. Expert Opin Drug Deliv 2006; 3: 541-48.
23. GLUMETZA® (metformin hydrochloride) extended release tablet. http://www.rxlist.com/glumetza-drug.htm (Accessed Jan 20, 2012).
24. Proquin® XR (ciprofloxacin hydrochloride) extended-release tablets. http://www.rxlist.com/proquin-xr-drug.htm (Accessed Jan 20, 2012).
25. Keats TE, Sistrom C. Gatrointestinal system. In: Atlas of radiologic measurement. Mosby Inc., St. Louis Missouri, 2001; pp. 400-403.
26. Chen C, Cowles VE, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and the effect of dose escalation and food. J Clin Pharmacol 2011; 51: 346-58.
27. Chien YW. Oral drug delivery and delivery systems. In: Swarbrick J Ed. Novel drug delivery systems. Marcel Dekker. New York, 1992; pp. 159-63.
28. Depomed study report: Comparison of the pharmacokinetics of gabapentin gastric retentive tablets versus an immediate release capsule in beagle dog. 2007; May 4.
29. Gupta A, Ciavarella AB, Sayeed VA, Khan MA, Faustino PJ. Development and application of a validated HPLC method for the analysis of dissolution samples of gabapentin drug products. J Pharmaceut Biomed Anal 2008; 46: 181-86.
30. Gordi T, Hou E, Sreeneeranj K, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediaterelease tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 2008; 30: 909-16.
31. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280:1837-42.
32. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94: 215-24.
33. Odrcich M, Bailey JM, Cahill CM, Gilron I. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain 2006; 120: 207-12.
34. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia, results of a double-blind, randomized, Placebocontrolled clinical trial. Clin J Pain 2009; 25: 185-92.